ESR1 and breast cancer: Recently, clinical cross-resistance mediated by PTEN loss has been shown between CDK4/6 inhibitors and alpelisib, an alpha-specific PI3K inhibitor (PI3Ki) recently approved for the treatment of PIK3CA-mutated ER+ advanced BC that progressed on previous endocrine therapy (79, 80) (Table 2).